Evidence map›Paper›PMID 28769760›Full record

ReviewFrontiers in molecular neuroscience2017

Implications of DNA Methylation in Parkinson's Disease.

Ernesto Miranda-Morales, Karin Meier, Ada Sandoval-Carrillo, José Salas-Pacheco, Paola Vázquez-Cárdenas, Oscar Arias-Carrión

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 102 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ernesto Miranda-MoralesUnidad de Trastornos del Movimiento y Sueño, Hospital General Dr. Manuel Gea GonzálezMexico City, Mexico.
Karin MeierDepartamento de Genética Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de MéxicoMexico City, Mexico.
Ada Sandoval-CarrilloInstituto de Investigación Científica, Universidad Juárez del Estado de DurangoDurango, Mexico.
José Salas-PachecoInstituto de Investigación Científica, Universidad Juárez del Estado de DurangoDurango, Mexico.
Paola Vázquez-CárdenasClínica de Obesidad, Hospital General Dr. Manuel Gea GonzálezMexico City, Mexico.
Oscar Arias-CarriónUnidad de Trastornos del Movimiento y Sueño, Hospital General Dr. Manuel Gea GonzálezMexico City, Mexico.
Hospital General Dr. Manuel Gea Gonzalez · MXUniversidad Juárez del Estado de Durango · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has been 200 years since Parkinson's disease (PD) was first described, yet many aspects of its etiopathogenesis remain unclear. PD is a progressive and complex neurodegenerative disorder caused by genetic and environmental factors including aging, nutrition, pesticides and exposure to heavy metals. DNA methylation may be altered in response to some of these factors; therefore, it is proposed that epigenetic mechanisms, particularly DNA methylation, can have a fundamental role in gene-environment interactions that are related with PD. Epigenetic changes in PD-associated genes are now widely studied in different populations, to discover the mechanisms that contribute to disease development and identify novel biomarkers for early diagnosis and future pharmacological treatment. While initial studies sought to find associations between promoter DNA methylation and the regulation of associated genes in PD brain tissue, more recent studies have described concordant DNA methylation patterns between blood and brain tissue DNA. These data justify the use of peripheral blood samples instead of brain tissue for epigenetic studies. Here, we summarize the current data about DNA methylation changes in PD and discuss the potential of DNA methylation as a potential biomarker for PD. Additionally, we discuss environmental and nutritional factors that have been implicated in DNA methylation. Although the search for significant DNA methylation changes and gene expression analyses of PD-associated genes have yielded inconsistent and contradictory results, epigenetic modifications remain under investigation for their potential to reveal the link between environmental risk factors and the development of PD.

Indexed as

5-methylcytosinealpha-synucleinDNA methylationepigeneticsfolateneurodegenerationParkinson disease

Identifiers

PMID28769760
PMCPMC5513956
OpenAlexW2738551041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.